Market revenue in 2021 | USD 2,894.2 million |
Market revenue in 2028 | USD 5,965.4 million |
Growth rate | 10.9% (CAGR from 2021 to 2028) |
Largest segment | Gene therapy |
Fastest growing segment | Cell Therapy |
Historical data covered | 2018 - 2020 |
Base year for estimation | 2021 |
Forecast period covered | 2022 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Gene Therapy, Cell Therapy, Tissue Engineered, Others (Combined ATMPs, for example biodegradable matric or scaffold) |
Key market players worldwide | AGC Inc, Catalent Inc, Lonza Group Ltd, Wuxi AppTec Co Ltd, Cencora Inc, Resonac Holdings Corp, Thermo Fisher Scientific Inc, CELONIC, Bio Elpida, CGT Catapult, Rentschler Biopharma SE |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to advanced therapy medicinal products cdmo market will help companies and investors design strategic landscapes.
Gene therapy was the largest segment with a revenue share of 53% in 2021. Horizon Databook has segmented the North America advanced therapy medicinal products cdmo market based on gene therapy, cell therapy, tissue engineered, others (combined atmps, for example biodegradable matric or scaffold) covering the revenue growth of each sub-segment from 2018 to 2028.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America advanced therapy medicinal products cdmo market , including forecasts for subscribers. This continent databook contains high-level insights into North America advanced therapy medicinal products cdmo market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account